It would appear that the FDA is now in the position of holding up patient access to an approvable and valuable medication. To the extent that resolution of the Hayward issue has been due to FDA foot-dragging, that may change given what is now at stake for Parkinson sufferers. Or perhaps Impax can come up with a way to get its alternate strategy reviewed and approved. Either way, it seems to be a question of "when" and not "if" Rytary is approved. And there is no deadline, meaning approval can come at any time without warning. If you are not long when it happens, you will miss a pop of several $$ IMO. I see a diminished downside risk, and a stronger argument for being long. I would be very surprised to see any real selloff in the stock tomorrow.